RU2159617C2 - Производные ксантина, их стереоизомеры и физиологически переносимые соли, фармацевтическая композиция, обладающая уменьшающей патологическую гиперактивность эозинофильных гранулятов активностью - Google Patents

Производные ксантина, их стереоизомеры и физиологически переносимые соли, фармацевтическая композиция, обладающая уменьшающей патологическую гиперактивность эозинофильных гранулятов активностью Download PDF

Info

Publication number
RU2159617C2
RU2159617C2 RU96121791/14A RU96121791A RU2159617C2 RU 2159617 C2 RU2159617 C2 RU 2159617C2 RU 96121791/14 A RU96121791/14 A RU 96121791/14A RU 96121791 A RU96121791 A RU 96121791A RU 2159617 C2 RU2159617 C2 RU 2159617C2
Authority
RU
Russia
Prior art keywords
methyl
xanthine
ethyl
xanthine derivatives
benzyl
Prior art date
Application number
RU96121791/14A
Other languages
English (en)
Russian (ru)
Other versions
RU96121791A (ru
Inventor
Геберт Ульрих
Анагностопулос Хиристо
Крегель Клаус
Капп Александер
Original Assignee
Хехст АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хехст АГ filed Critical Хехст АГ
Publication of RU96121791A publication Critical patent/RU96121791A/ru
Application granted granted Critical
Publication of RU2159617C2 publication Critical patent/RU2159617C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU96121791/14A 1994-04-05 1995-03-21 Производные ксантина, их стереоизомеры и физиологически переносимые соли, фармацевтическая композиция, обладающая уменьшающей патологическую гиперактивность эозинофильных гранулятов активностью RU2159617C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4411660.8 1994-04-05
DE4411660A DE4411660A1 (de) 1994-04-05 1994-04-05 Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung

Publications (2)

Publication Number Publication Date
RU96121791A RU96121791A (ru) 1999-02-10
RU2159617C2 true RU2159617C2 (ru) 2000-11-27

Family

ID=6514636

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96121791/14A RU2159617C2 (ru) 1994-04-05 1995-03-21 Производные ксантина, их стереоизомеры и физиологически переносимые соли, фармацевтическая композиция, обладающая уменьшающей патологическую гиперактивность эозинофильных гранулятов активностью

Country Status (11)

Country Link
EP (1) EP0758239A1 (zh)
JP (1) JPH09510983A (zh)
KR (1) KR100373948B1 (zh)
CN (1) CN1098686C (zh)
AU (1) AU695488B2 (zh)
CA (1) CA2187081A1 (zh)
DE (1) DE4411660A1 (zh)
HU (1) HUT74732A (zh)
RU (1) RU2159617C2 (zh)
UA (1) UA39136C2 (zh)
WO (1) WO1995026727A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US5985592A (en) * 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
WO1999049865A1 (en) * 1998-03-31 1999-10-07 Mayo Foundation For Medical Education And Research Use of platelet activating factor (paf) inhibitors to inhibit il-5 induced eosinophil activation or degranulation
AR040232A1 (es) * 2002-05-31 2005-03-23 Schering Corp Proceso para preparar inhibidores de la xantina fosfodiesterasa v, y precursores de los mismos
SI1509525T1 (sl) * 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918297D0 (en) * 1989-08-10 1989-09-20 Beecham Group Plc Novel treatment
DD298051A5 (de) * 1989-08-16 1992-02-06 ��@���������@�������k�� Verfahren zur herstellung eines therapeutischen agens zur behandlung von verdauungskrankheiten
GB9023783D0 (en) * 1990-11-01 1990-12-12 Celltech Ltd Pharmaceutical product
EP0490181A1 (en) * 1990-11-30 1992-06-17 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for preparation of a medicament having immunosuppressing activity
WO1993003728A1 (en) * 1991-08-27 1993-03-04 Temple University Of The Commonwealth System Of Xanthine suppression of antigen activation of t- or b-cells
IL99368A (en) * 1991-09-02 1996-01-19 Teva Pharma Preparations for the treatment of psoriasis and atopic dermatitis, which contain the result of xanthine
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
МАШКОВСКИЙ М.Д. Лекарственные средства. - М., 1986, ч.1, с.307-308. *

Also Published As

Publication number Publication date
HU9602712D0 (en) 1996-11-28
DE4411660A1 (de) 1995-10-12
KR100373948B1 (ko) 2003-06-09
UA39136C2 (uk) 2001-06-15
CN1145029A (zh) 1997-03-12
HUT74732A (en) 1997-02-28
AU1951095A (en) 1995-10-23
EP0758239A1 (de) 1997-02-19
CN1098686C (zh) 2003-01-15
KR970702044A (ko) 1997-05-13
JPH09510983A (ja) 1997-11-04
AU695488B2 (en) 1998-08-13
CA2187081A1 (en) 1995-10-12
WO1995026727A1 (de) 1995-10-12

Similar Documents

Publication Publication Date Title
KR100516382B1 (ko) 퀴놀린 유도체
JP4015547B2 (ja) キサンチンホスホジエステラーゼｖインヒビター
EP0103497B1 (fr) Nouveaux dérivés de la xanthine, leur procédé de préparation et les compositions pharmaceutiques les renfermant
JP2550301B2 (ja) ビシナルジヒドロキシアルキルキサンチン含有薬剤
JPH0216315B2 (zh)
JPH0692407B2 (ja) Ｎ▲上６▼−ジ置換プリン誘導体、その製法及び該誘導体を含有するアレルギ−性疾患の治療剤
JPH0788382B2 (ja) 第三ヒドロキシアルキルキサンチン、それらの製造法及びそれを含有する治療剤
EP0559893A1 (en) Xanthine derivative
US4264613A (en) Piperidylbenzimidazolinone compounds
EP0205362B1 (fr) Dérivés quinolylglycinamides, leur procédé de préparation et leur application thérapeutique en tant que psychotropes
RU2159617C2 (ru) Производные ксантина, их стереоизомеры и физиологически переносимые соли, фармацевтическая композиция, обладающая уменьшающей патологическую гиперактивность эозинофильных гранулятов активностью
JPH0475911B2 (zh)
CA1075237A (en) Purine derivatives
JPS63295566A (ja) キノキサリノン誘導体
CS196357B2 (en) Process for preparing new basic substituted derivatives of xanthine
JPS6363547B2 (zh)
JPS6143183A (ja) 新規２ｈ‐１‐ベンゾピラン‐２‐オン誘導体、その製法およびこれを含有する抗アレルギー性疾患治療剤
US5017572A (en) Derivatives of 1-[3-(4-hydroxyphenyl) 1-hydroxy 1-propyl] benzene substituted in position 2 by an aminoalkyleneoxy chain, the method of preparing same and the application thereof to therapeutics
EP0292400A1 (fr) Dérivés du Spiro (4,5) décane, leur procédé de préparation et les compositons pharmaceutiques les renfermant
JPH06100448A (ja) シクロアルカン誘導体、その製造方法およびそれを含有するロイコトリエンが介在する疾患または症状に使用するための調剤学的組成物
US4797498A (en) Flavonoxypropanolamines and esters of flavonoxypropanolamines as antiarrhythmic agents
EP0308059B1 (en) 1,2,3,4-tetrahydroisoquinoline antiarrhythmic agents
US20020010333A1 (en) Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation
WO1999020623A1 (en) Indole derivative useful as endothelin receptor antagonist
JPH06102660B2 (ja) 新規なモルホリン誘導体およびこれらの誘導体を含有する医薬組成物